Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1981 Oct;34(1):192–199. doi: 10.1128/iai.34.1.192-199.1981

Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.

R D Dix, L Pereira, J R Baringer
PMCID: PMC350842  PMID: 6271681

Abstract

Monoclonal antibodies HCl and HD1, directed against herpes simplex virus type 1 (HSV-1) glycoproteins gC and gD, respectively, were evaluated for their ability to passively immunize mice against acute virus-induced neurological disease after footpad inoculation with HSV-1 or herpes simplex virus type 2 (HSV-2). Control virus-infected mice receiving a single intraperitoneal injection of normal serum died within 7 to 10 days after the spread of virus from footpad to spinal cord and brain. However, a single intraperitoneal injection of either HCl or HD1 antibody protected mice from neurological illness and death when administered to HSV-1 (strain HTZ)-infected mice at either 2 h before virus challenge or at 24 h after virus inoculation. To determine the in vivo specificity of the antibodies, passive transfer studies were performed with mice infected with the MP strain of HSV-1, a mutant of HSV-1 (mP) which is defective in the production of glycoprotein gC. Whereas HD1 antibody decreased the incidence of neurological illness in MP- and mP-infected mice, HCl antibody, which protected mP-infected animals, failed to protect mice infected with the MP strain. When HD1 antibody was administered to HSV-2 (strain G)-infected mice at either 2 h before virus challenge or at 6 h (but not 24 h) after virus inoculation, 100% of the infected animals receiving HD1 antibody survived. In contrast, 100% of HSV-2 (strain G)-infected animals passively immunized with HCl antibody developed neurological illness and died. These results provide in vivo evidence that the HSV-induced glycoprotein gC expresses type-specific antigenic determinants, whereas glycoprotein gD expresses type-common determinants.

Full text

PDF
192

Images in this article

194Image
on p.194

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baron S., Worthington M. G., Williams J., Gaines J. W. Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice. Nature. 1976 Jun 10;261(5560):505–506. doi: 10.1038/261505a0. [DOI] [PubMed] [Google Scholar]
  2. Bone D. R., Courtney R. J. A temperature-sensitive mutant of herpes simplex virus type 1 defective in the synthesis of the major capsid polypeptide. J Gen Virol. 1974 Jul;24(1):17–27. doi: 10.1099/0022-1317-24-1-17. [DOI] [PubMed] [Google Scholar]
  3. Cohen G. H., Katze M., Hydrean-Stern C., Eisenberg R. J. Type-common CP-1 antigen of herpes simplex virus is associated with a 59,000-molecular-weight envelope glycoprotein. J Virol. 1978 Jul;27(1):172–181. doi: 10.1128/jvi.27.1.172-181.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cook M. L., Stevens J. G. Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection. Infect Immun. 1973 Feb;7(2):272–288. doi: 10.1128/iai.7.2.272-288.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Courtney R. J. Immunologic and biochemical characterization of individual polypeptides induced by herpes simplex virus types 1 and 2. Adv Pathobiol. 1976;(5):87–103. [PubMed] [Google Scholar]
  6. Dix R. D., Courtney R. J. Effects of cytochalasin B on herpes simplex virus type 1 replication. Virology. 1976 Mar;70(1):127–135. doi: 10.1016/0042-6822(76)90242-7. [DOI] [PubMed] [Google Scholar]
  7. Douglas R. G., Jr, Couch R. B. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol. 1970 Feb;104(2):289–295. [PubMed] [Google Scholar]
  8. Heine J. W., Spear P. G., Roizman B. Proteins specified by herpes simplex virus. VI. Viral proteins in the plasma membrane. J Virol. 1972 Mar;9(3):431–439. doi: 10.1128/jvi.9.3.431-439.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Honess R. W., Powell K. L., Robinson D. J., Sim C., Watson D. H. Type specific and type common antigens in cells infected with herpes simplex virus type 1 and on the surfaces of naked and enveloped particles of the virus. J Gen Virol. 1974 Feb;22(2):159–169. doi: 10.1099/0022-1317-22-2-159. [DOI] [PubMed] [Google Scholar]
  10. Klein R. J. Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice. J Gen Virol. 1980 Aug;49(2):401–405. doi: 10.1099/0022-1317-49-2-401. [DOI] [PubMed] [Google Scholar]
  11. Kristensson K., Lycke E., Sjöstrand J. Spread of herpes simplex virus in peripheral nerves. Acta Neuropathol. 1971;17(1):44–53. doi: 10.1007/BF00684740. [DOI] [PubMed] [Google Scholar]
  12. Luyet F., Samra D., Soneji A., Marks M. I. Passive immunization in experimental Herpesvirus hominis infection of newborn mice. Infect Immun. 1975 Dec;12(6):1258–1261. doi: 10.1128/iai.12.6.1258-1261.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Manservigi R., Spear P. G., Buchan A. Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3913–3917. doi: 10.1073/pnas.74.9.3913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McKendall R. R. Comparative neurovirulence and latency of HSV1 and HSV2 following footpad inoculation in mice. J Med Virol. 1980;5(1):25–32. doi: 10.1002/jmv.1890050104. [DOI] [PubMed] [Google Scholar]
  15. McKendall R. R., Klassen T., Baringer J. R. Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread. Infect Immun. 1979 Feb;23(2):305–311. doi: 10.1128/iai.23.2.305-311.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Norrild B., Shore S. L., Nahmias A. J. Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides. J Virol. 1979 Dec;32(3):741–748. doi: 10.1128/jvi.32.3.741-748.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Oakes J. E., Davis W. B., Taylor J. A., Weppner W. A. Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice. Infect Immun. 1980 Aug;29(2):642–649. doi: 10.1128/iai.29.2.642-649.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Oakes J. E. Invasion of the central nervous system by herpes simplex virus type 1 after subcutaneous inoculation of immunosuppressed mice. J Infect Dis. 1975 Jan;131(1):51–57. doi: 10.1093/infdis/131.1.51. [DOI] [PubMed] [Google Scholar]
  19. Oakes J. E. Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun. 1975 Jul;12(1):166–172. doi: 10.1128/iai.12.1.166-172.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Oakes J. E., Rosemond-Hornbeak H. Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infect Immun. 1978 Aug;21(2):489–495. doi: 10.1128/iai.21.2.489-495.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oleske J. M., Ashman R. B., Kohl S., Shore S. L., Starr S. E., Wood P., Nahmias A. J. Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol. 1977 Mar;27(3):446–453. [PMC free article] [PubMed] [Google Scholar]
  22. Openshaw H., Asher L. V., Wohlenberg C., Sekizawa T., Notkins A. L. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol. 1979 Jul;44(1):205–215. doi: 10.1099/0022-1317-44-1-205. [DOI] [PubMed] [Google Scholar]
  23. Pereira L., Klassen T., Baringer J. R. Type-common and type-specific monoclonal antibody to herpes simplex virus type 1. Infect Immun. 1980 Aug;29(2):724–732. doi: 10.1128/iai.29.2.724-732.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Powell K. L., Courtney R. J. Polypeptide synthesized in herpes simplex virus type 2-infected HEp-2 cells. Virology. 1975 Jul;66(1):217–228. doi: 10.1016/0042-6822(75)90192-0. [DOI] [PubMed] [Google Scholar]
  25. Price R. W., Walz M. A., Wohlenberg C., Notkins A. L. Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization. Science. 1975 May 30;188(4191):938–940. doi: 10.1126/science.166432. [DOI] [PubMed] [Google Scholar]
  26. Rager-Zisman B., Allison A. C. Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection. J Immunol. 1976 Jan;116(1):35–40. [PubMed] [Google Scholar]
  27. Rouse B. T., Wardley R. C., Babiuk L. A. The role of antibody dependent cytotoxicity in recovery from herpesvirus infections. Cell Immunol. 1976 Mar 1;22(1):182–186. doi: 10.1016/0008-8749(76)90019-8. [DOI] [PubMed] [Google Scholar]
  28. Shore S. L., Black C. M., Melewicz F. M., Wood P. A., Nahmias A. J. Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol. 1976 Jan;116(1):194–201. [PubMed] [Google Scholar]
  29. Sim C., Watson D. H. The role of type specific and cross reacting structural antigens in the neutralization of herpes simplex virus types 1 and 2. J Gen Virol. 1973 May;19(2):217–233. doi: 10.1099/0022-1317-19-2-217. [DOI] [PubMed] [Google Scholar]
  30. Spear P. G. Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells. J Virol. 1976 Mar;17(3):991–1008. doi: 10.1128/jvi.17.3.991-1008.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES